ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
High Rates of Dysplasia in a Population-Based Analysis of "Incidental" Barrett's Esophagus.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND &
aimsCurrent screening and surveillance in Barrett's esophagus (BE) identifies only a minority of esophageal adenocarcinomas. Novel testing modalities may allow broadening of indications for BE screening. Whether such efforts are warranted depends on the characteristics of additional BE cases discovered, and their risk of progression. This study used national benchmarking data to characterize "incidental" BE.
methodsUpper endoscopies with BE in GI Quality Improvement Consortium (GIQuIC) Registry from January 2015 to July 2022 were categorized by indication: BE screening, surveillance, or non-BE-related ("incidental"). Demographics, disease-specific characteristics, and dysplasia detection rate (DDR: low and high-grade dysplasia) were compared, as well as adherence to quality indicators.
resultsOf 88,370 cases (67.3% male; 74.0% white) with histologically confirmed intestinal metaplasia, 88.1% were nondysplastic (NDBE). Most cases were performed for BE surveillance (65.0%). Incidental BE (16.4%) occurred almost as frequently as BE found in screening exams (18.6%). The mean BE segment length was longer in incidental BE (2.9 cm) than BE screening (2.6 cm) or surveillance (2.8 cm; P < .001). DDR was actually highest in incidental BE (3.8%), compared with surveillance or screening exams (2.5% and 3.3%; P < .0001). Adherence to appropriate surveillance was similar in incidental and screening (54.5% and 51.9%), with higher adherence in the surveillance group (73.6%; P < .0001).
conclusionsBE is found incidentally at rates approaching those seen in dedicated screening exams. Incidental BE is not only common but has similar or worse high-risk features as BE in traditional screening and surveillance populations, given segment length and dysplasia yield. Refinement of BE screening programs could yield cases of similar risk of progression as traditional programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.